Efficacy and safety of percutaneous microwave coagulation therapy followed by 125I seed brachytherapy for VX2 hepatic tumors in a rabbit model

Yu,Dong-Sheng; Chang,Hong; Sommer,Christof-Matthias; Qu,Wei-Li; Xu,Wen-Jian; Yang,Ren-Jie; Zhao,Peng

doi:10.3892/etm.2013.1088

Efficacy and safety of percutaneous microwave coagulation therapy followed by 125I seed brachytherapy for VX2 hepatic tumors in a rabbit model

Authors:
- Dong-Sheng Yu
- Hong Chang
- Christof-Matthias Sommer
- Wei-Li Qu
- Wen-Jian Xu
- Ren-Jie Yang
- Peng Zhao
View Affiliations

Affiliations: Department of Interventional Medicine, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Pediatrics, The Affiliated Hospital of Qingdao University Medical College, Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg D-69120, Germany, Department of Interventional Therapy, School of Oncology, Peking University, Beijing 100036, P.R. China
Published online on: April 29, 2013 https://doi.org/10.3892/etm.2013.1088
Pages: 159-163

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to evaluate the efficacy and safety of percutaneous microwave coagulation therapy (PMCT) followed by 125I seed brachytherapy for VX2 liver cancer in rabbits. Eighty New Zealand rabbits were injected with suspensions of VX2 tumor cells to create an animal model. The rabbits were randomly divided into 4 groups (n=20); the control, PMCT, 125I seed brachytherapy and combination groups. Group A was treated with PMCT at 40 W for 120 sec, group B was treated with 125I seed brachytherapy and group C was treated with PMCT followed by 125I seed brachytherapy. Group D were not treated and served as the control group. At 21 days after treatment, the rabbits were sacrificed for pathological assessment. The complete tumor necrosis rate was 19 out of 20 tumors (95%) in group C, 6 (30%) in group A, 0 (0%) in group B and 0 (0%) in the control group. The complete tumor necrosis rate was observed to be significantly different between groups C and A, and between groups C and B (P<0.01). No intraheptic metastasis occurred in group C, compared with an incidence of 7 (35%) in group A, 2 (10%) in group B and 20 (100%) in the control group. Between groups C and A, and between groups C and D, the intraheptic metastasis rate was statistically significant (P<0.01). PMCT followed by 125I seed brachytherapy increased the rate of carcinoma necrosis and decreased carcinoma metastasis in the VX2 rabbit model. This combined treatment is a safe, effective and minimally invasive therapeutic option for liver cancer.

View Figures

View References

1.	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Lencioni R: Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 83:216–224. 2012. View Article : Google Scholar : PubMed/NCBI
3.	Ferenci P, Fried M, Labrecque D, et al: Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 44:239–245. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
5.	Cormier JN, Thomas KT, Chari RS and Pinson CW: Management of hepatocellular carcinoma. J Gastrointest Surg. 10:761–780. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Marelli L, Stigliano R, Triantos C, et al: Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 32:594–606. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Takayasu K: Chemoembolization for unresectable hepatocellular carcinoma in Japan. Oncology. 78(Suppl 1): 135–141. 2010. View Article : Google Scholar
8.	Liapi E and Geschwind JF: Chemoembolization for primary and metastatic liver cancer. Cancer J. 16:156–162. 2010. View Article : Google Scholar : PubMed/NCBI
9.	Itoh S, Ikeda Y, Kawanaka H, et al: Efficacy of surgical microwave therapy in patients with unresectable hepatocellular carcinoma. Ann Surg Oncol. 18:3650–3656. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Carrafiello G, Laganà D, Mangini M, et al: Microwave tumors ablation: principles, clinical applications and review of preliminary experiences. Int J Surg. 6(Suppl 1): S65–S69. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Liang P, Dong BW, Yu XL, et al: Ultrasound-guided percutaneous microwave coagulation therapy for hepatic metastases. Zhonghua Zhong Liu Za Zhi. 26:301–304. 2004.(In Chinese).
12.	Lee W, Daly BD, DiPetrillo TA, et al: Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg. 75:237–243. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Trombetta MG, Colonias A, Makishi D, et al: Tolerance of the aorta using intraoperative iodine-125 interstitial brachytherapy in cancer of the lung. Brachytherapy. 7:50–54. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Chen HH, Jia RF, Yu L, Zhao MJ, Shao CL and Cheng WY: Bystander effects induced by continuous low-dose-rate ¹²⁵I seeds potentiate the killing action of irradiation on human lung cancer cells in vitro. Int J Radiat Oncol Biol Phys. 72:1560–1566. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Lencioni R and Crocetti L: Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol. 10:38–46. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J and Bartolozzi C: Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 234:961–967. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Shibata T, Iimuro Y, Yamamoto Y, et al: Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 223:331–337. 2002. View Article : Google Scholar
18.	Ricke J, Wust P, Stohlmann A, et al: CT-guided brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys. 58:1496–1505. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Wang JJ, Yuan HS, Li JN, Jiang WJ, Jiang YL and Tian SQ: Interstitial permanent implantation of ¹²⁵I seeds as salvage therapy for re-recurrent rectal carcinoma. Int J Colorectal Dis. 24:391–399. 2009.PubMed/NCBI
20.	Wang J, Yuan H, Ma Q, et al: Interstitial 125I seeds implantation to treat spinal metastatic and primary paraspinal malignancies. Med Oncol. 27:319–326. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF and Goldberg SN: Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multi-center study. Radiology. 226:441–451. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Bowles BJ, Machi J, Limm WM, et al: Safety and efficacy of radiofrequency thermal ablation in advanced liver tumors. Arch Surg. 136:864–869. 2001. View Article : Google Scholar : PubMed/NCBI
23.	Durand F and Valla D: Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 42(Suppl1): S100–S107. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Dupuy DE and Goldberg SN: Image-guided radiofrequency tumor ablation: challenges and opportunities-part II. J Vasc Interv Radiol. 12:1135–1148. 2001. View Article : Google Scholar : PubMed/NCBI